A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma

Chakraborty, R., Yan, Y., & Royal, M. (2021). A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 138(Supplement 1), 4763–4763. https://doi.org/10.1182/blood-2021-150783
Authors:
Rajshekhar Chakraborty
Ying Yan
Mike A. Royal
Affiliated Authors:
Rajshekhar Chakraborty
Columbia Affiliation:
Subjects:
Diagnosis and Treatment of Multiple Myeloma (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Synthesis and Biological Activities of Quinoxaline Derivatives (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2021-150783
DOI:
10.1182/blood-2021-150783
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: